Goodwill, IPR&D and Other Intangible Assets, Net (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Nov. 12, 2014
Intangible Assets, Net
Goodwill	$ 205,824,000		$ 205,824,000
Finite-Lived Intangible Assets, Net [Abstract]
Cost	813,993,000		813,993,000
Accumulated Amortization	16,667,000		5,185,000
Net	797,326,000		808,808,000
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Intangible assets, net	876,426,000		887,908,000
Expected future annual amortization expense
Remainder of Year Ended December 31, 2015	40,404,000
Year Ended December 31, 2016	64,977,000
Year Ended December 31, 2017	76,679,000
Year Ended December 31, 2018	84,359,000
Year Ended December 31, 2019	55,746,000
Total	322,165,000
Lumara Health
Intangible Assets, Net
Goodwill			205,800,000	205,824,000
Useful life	20 years
PlasmaTech Biopharmaceuticals Inc
Intangible Assets, Net
Useful life	10 years
Licensing Agreements
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	16,667,000		5,185,000
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Cost	893,093,000		893,093,000
Intangible assets, net	876,426,000		887,908,000
Licensing Agreements | Lumara Health
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Cost	79,100,000		79,100,000
Net	79,100,000		79,100,000
Licensing Agreements
Intangible Assets, Net
Amortization of intangible assets	11,500,000
Licensing Agreements | Maximum
Intangible Assets, Net
Amortization of intangible assets		100,000
Licensing Agreements | Lumara Health
Finite-Lived Intangible Assets, Net [Abstract]
Cost	797,100,000		797,100,000
Accumulated Amortization	16,245,000		4,834,000
Net	780,855,000		792,266,000
Licensing Agreements | PlasmaTech Biopharmaceuticals Inc
Finite-Lived Intangible Assets, Net [Abstract]
Cost	16,893,000		16,893,000
Accumulated Amortization	422,000		351,000
Net	$ 16,471,000		$ 16,542,000